At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SRRK Scholar Rock Holding Corp
Market Closed 04-02 16:00:00 EDT
50.01
+0.66
+1.34%
盘后50.01
+0.000.00%
19:59 EDT
High50.36Low47.96Vol2.03M
Open48.49D1 Closing49.35Amplitude4.86%
Mkt Cap5.75BTradable Cap4.52BTotal Shares115.00M
T/O100.79MT/O Rate2.24%Tradable Shares90.38M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Scholar Rock Holding Is Maintained at Outperform by Wedbush
Dow Jones  ·  04-01 20:49
Scholar Rock Holding Is Maintained at Outperform by Wedbush
Scholar Rock Holding Corp : Raymond James Raises Target Price to $60 From $53
THOMSON REUTERS  ·  04-01
Scholar Rock Holding Corp : Raymond James Raises Target Price to $60 From $53
Scholar Rock price target raised to $58 from $51 at BofA
TIPRANKS  ·  04-01
Scholar Rock price target raised to $58 from $51 at BofA
BUZZ-U.S. STOCKS ON THE MOVE -Shake Shack, Perpetua, Caribou Biosciences
Reuters  ·  04-01
BUZZ-U.S. STOCKS ON THE MOVE -Shake Shack, Perpetua, Caribou Biosciences
Scholar Rock rises 15.5%
TIPRANKS  ·  03-31
Scholar Rock rises 15.5%
Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating
MT Newswires Live  ·  03-31
Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating
What Sent Scholar Rock Holding Stock (SRRK) Higher Today?
TIPRANKS  ·  03-31
What Sent Scholar Rock Holding Stock (SRRK) Higher Today?
Scholar Rock up 12% at $48.27 after resubmitting BLA to FDA for apitegromab
TIPRANKS  ·  03-31
Scholar Rock up 12% at $48.27 after resubmitting BLA to FDA for apitegromab
BUZZ-Scholar Rock up after refiling FDA application for genetic disorder drug
Reuters  ·  03-31
BUZZ-Scholar Rock up after refiling FDA application for genetic disorder drug
Scholar Rock Resubmits Biologics License Application for Apitegromab to US FDA
MT Newswires Live  ·  03-31
Scholar Rock Resubmits Biologics License Application for Apitegromab to US FDA
Scholar Rock Holding Corp: Anticipates FDA Acceptance of Bla Within 30 Days and a Review Period of up to 6 Months From Date of Resubmission
THOMSON REUTERS  ·  03-31
Scholar Rock Holding Corp: Anticipates FDA Acceptance of Bla Within 30 Days and a Review Period of up to 6 Months From Date of Resubmission
Scholar Rock Holding: During Meeting & FDA Site Visit, No Additional Corrective Actions Were Requested by FDA to Novo Nordisk's Remediation Plan
THOMSON REUTERS  ·  03-31
Scholar Rock Holding: During Meeting & FDA Site Visit, No Additional Corrective Actions Were Requested by FDA to Novo Nordisk's Remediation Plan
Scholar Rock Resubmits Biologics License Application (Bla) to FDA for Apitegromab for Treatment of Children and Adults With Spinal Muscular Atrophy (Sma)
THOMSON REUTERS  ·  03-31
Scholar Rock Resubmits Biologics License Application (Bla) to FDA for Apitegromab for Treatment of Children and Adults With Spinal Muscular Atrophy (Sma)
Scholar Rock Holding Corp: Pdufa Action Date Expected in Late September 2026
THOMSON REUTERS  ·  03-31
Scholar Rock Holding Corp: Pdufa Action Date Expected in Late September 2026
Is Scholar Rock Holding (SRRK) Still Attractive After Recent Share Price Pullback?
Simply Wall St.  ·  03-28
Is Scholar Rock Holding (SRRK) Still Attractive After Recent Share Price Pullback?
Wedbush Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
TIPRANKS  ·  03-20
Wedbush Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT)
TIPRANKS  ·  03-20
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT)
Scholar Rock jumps 8% after Cantor says Genentech stopped SMA drug
TIPRANKS  ·  03-20
Scholar Rock jumps 8% after Cantor says Genentech stopped SMA drug
Does Scholar Rock (SRRK) Offer Long-Term Value After Recent Share Price Weakness?
Simply Wall St.  ·  03-20
Does Scholar Rock (SRRK) Offer Long-Term Value After Recent Share Price Weakness?
Scholar Rock reports inducement equity grants covering 60,655 shares under Nasdaq Rule 5635(c)(4)
Reuters  ·  03-14
Scholar Rock reports inducement equity grants covering 60,655 shares under Nasdaq Rule 5635(c)(4)
No data available

Introduction

Company Name.
Scholar Rock Holding Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Issue price:
--